Rfb002, rhufab v2 (DrugBank: rhuFab V2)
1 disease告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
166 | 弾性線維性仮性黄色腫 | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2006-006231-49-DE (EUCTR) | 24/07/2007 | 06/03/2007 | Ranibizumab in choroidal neovascularization (CNV) due to Pseudoxanthoma elasticum (PXE, Groenblad-Strandberg Syndrome) - PXE-CNV 06 | Ranibizumab in choroidal neovascularization (CNV) due to Pseudoxanthoma elasticum (PXE, Groenblad-Strandberg Syndrome) - PXE-CNV 06 | Pseudoxanthoma elasticum (PXE) is an inherited systemic disease characterized by changes in the elastic tissue. Pseudoxanthoma elasticum mainly affects the skin, eyes, heart, and GI system. The cutaneous and ocular findings of PXE are referred to as Grönblad-Strandberg syndrome. Pseudoxanthoma elasticum may be autosomal dominant or autosomal recessive. In Pseudoxanthoma elasticum, choroidal nevoscualrization (CNV) is a frequently occuring complication in late stage disease MedDRA version: 8.1;Level: LLT;Classification code 10037150;Term: Pseudoxanthoma elasticum | Trade Name: Lucentis Product Name: Lucentis Product Code: RFB002 INN or Proposed INN: ranibizumab Other descriptive name: RFB002, rhuFab V2 | Department of Ophthalmology, Bonn University | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Germany |